Gold or Silver
26 Mar 2018
Re: BUY BUY BUY BUY BUY BUY Diagnostica Stago S.A.S (Stago), a privately held Company that provides reference tests and instrumentation in hemostasis, announced today that the company has entered a joint research agreement with Bristol-Myers Squibb Company (BMY) to develop an assay for measuring the circulating blood concentration of the oral Factor Xa inhibitor ELIQUIS® (apixaban). No commercial assay is presently available to specifically measure apixaban plasma concentration. Terms of the agreement were not disclosed.“Stago is pleased to have the opportunity to develop this test”, said Tristan Herve, Director of Pharmaceutical Development, “These oral Factor Xa inhibitors address an important unmet need for patients requiring anticoagulant therapy”.Stago has already completed prototype development and will be applying for health authority approvals of the assay worldwide. Diagnostica Stago retains 100 percent global development and commercialization rights for the assay.About Diagnostica StagoStago, created in 1945, is an IVD company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis and Thrombosis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Stago products are available in more than 100 countries in the world. Stago Group had over 2000 employees worldwide.
Gold or Silver
19 Mar 2018
Re: BUY BUY BUY BUY BUY BUY Could it be that the news of approval has leaked ?Best of Luck A
Gold or Silver
27 Feb 2018
Re: BUY BUY BUY BUY BUY BUY Here we go.Best of Luck A
Gold or Silver
22 Feb 2018
Re: BUY BUY BUY BUY BUY BUY Convincing breakout achieved.Could well hit above 50p on good news .Plenty of sustainable upside fro Mr Akers & C
Gold or Silver
21 Feb 2018
Re: BUY BUY BUY BUY BUY BUY 30p sell price & good volatility & Volume .Perhaps a few good hair days are there way.Best of Luck All Including Yiangos & I
Gold or Silver
02 Feb 2018
Re: BUY BUY BUY BUY BUY BUY 24p sell price is a huge Indicator.DO NOT Miss out .Best of Luck A
Gold or Silver
02 Feb 2018
BUY BUY BUY BUY BUY Chart says that US is well ahead of UK figures here .Best of Luck A
Gold or Silver
01 Feb 2018
Re: BUY BUY BUY For Akers Biosciences Inc (LON:AKR, NASDAQ:AKER), 2018 will be a defining year, according to chief executive John Gormally and its founder Raymond Akers.For having secured US$6.9mln of new investment, the company is focused on becoming cash flow positive and profitable.READ: Akers Biosciences unveils plans to raise US$6mlnThe turnaround probably can’t come quickly enough for shareholders in a business currently valued at less than the cash it has in the bank.A rerating will be effected if the company can successfully deliver on its fully-funded growth strategy set out in a 21-page Powerpoint presentation the firm delivered to would-be investors ahead of its most recent fund-raiser.Host of other productsThe cornerstone of the business will continue to be the PIFA rapid assay for an allergy to the blood thinner heparin; however, there’s a host of other products that it is hoped will help propel the company towards profitability.Chief among them is a new rapid test for Chlamydia that has huge potential: the PIFA PLUSS assay, which can deliver results in five minutes rather than the days it takes for a lab test.For women, at least, the simple blood test is far less invasive than the cervical swab currently used to collect samples.“This product, we believe, is going to be transformational for the company,” says its chairman Akers.“There is nothing like it in the world. It is the first assay that gives you the results in minutes and it is also the first blood test for Chlamydia.”It aims to work with the organisation Planned Parenthood in the US where it will also target clinics, college campus medical centres alongside government care-givers.Potential commercial partnersCEO Gormally said executives are lining up potential commercial partners who would help introduce PIFA PLUSS Chlamydia to the wider world; however, the product must first receive what’s called 510(k) approval from the US Food & Drug Administration.The process of securing this regulatory sign-off began last May and the medicines watchdog asked for more data from Akers in December.“We are nearer the end of the road with the FDA but it is very difficult to predict when it is going to happen. We think it is going to be sooner rather than later,” said Akers.The story doesn’t end with Chlamydia. The company’s health and wellness offering also has the potential to generate significant revenues, Gormally points out.Akers has developed an app that helps users track their health over time, which segues nicely with a number of products that tap into huge markets.It has breath test devices that help promote, track and encourage choices related to general health and wellbeing.Talking to network marketing companiesIt is talking to network marketing companies in a bid to open new sales channels, and the plan is to target weight loss centres, health and fitness clubs and doctors specialising in anti-aging.Sleepers in the Akers development pipeline are the PulmoHealth breath tests that detect biomarkers associated with lung cancer, asthma and chronic obstructive pulmonary disease (COPD).The numbers involved are mind-boggling: there are 1.6mln people diagnosed each year with lung cancer, 300mln suffer asthma, while 210mln smokers are currently being treated for COPD.An asthma clinical trial has been “highly successful” and the next step is to file with the FDA for 510(k) clearance.Cholesterol test already on saleAlready on sale is Tri-Cholesterol, the company’s rapid test that measures total, HDL (good) and LDL (bad) cholesterol.The product, the only one of its kind, is sold in major US drugstore chains under the FirstCheck brand and is another huge seam to mine for the business.“This last infusion of cash will get us across the line,” says Gormally, regarding the recent fundraising.“Everyone at Akers is supremely focused on making 2018 a profitable year.”
Gold or Silver
01 Feb 2018
Re: BUY BUY BUY Good run continues.Dependant on news.This undervalue company could do us very very well .Best of Luck A
Gold or Silver
17 Jan 2018
BUY BUY BUY Could be a good time ahead for Akers .Investors value us way above current MCAP .DO NOT Miss out Best of Luck AllCurrent 25 cents per sha
Gold or Silver
09 Jan 2018
About time For a change here .45 million shares can`t be wrong .Can they ?Best of Luck ALL
RichardLY
19 Dec 2017
Re: Finncap very positive "House broker finnCap" - Except that the first two words that were all you needed to read... Disaster!
Silveroil
30 Mar 2017
Re: RNS : new PIFA agreement Maybe turned the corner here
gretel
19 Dec 2016
RNS : new PIFA agreement Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA tests:[link] "John J. Gormally, Chief Executive Officer of Akers Bio, commented: "Akers Bio is delighted to have signed a three-year agreement with GNYHA, one of the premier group purchasing organizations in the United States healthcare sector. Their membership includes a diverse listing of prominent and large integrated delivery networks (IDNs) and hospitals. Enhanced access to GNYHA's network has the potential to dramatically increase domestic sales of our flagship product."
gretel
01 Dec 2016
Exciting RNS just out Worth noting in particular that First Check are a subsidiary of the mighty Alere Inc....[link] Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"
, a developer of rapid health information technologies, has signed a distribution agreement with First Check Diagnostics, LLC ("First Check", the major global diagnostic device and service provider, to serve as the exclusive distributor of the Company's rapid cholesterol self-test in the United States under their "First Check" brand. First Check products are sold through major retailers including, CVS, Rite Aid, Target, Kmart, Meijer, Giant Eagle, Stop & Shop, Giant and ShopKo. Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL" cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL" levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol. etc"
